Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
By
Admin
Summary
Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre|CISION® delivery platform, in patients with salivary gland cancer (SGC). The data showed robust tumor responses even in patients with very low FAP expression, with persistence of FAP expression observed despite tumor response. The company presented this data during the BIO International Conference and expects further data updates in Q3 2026.
Source
Twitter / XAvacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conferenceavacta.comKey quotes
· 2 pulledResponses observed in patients with very low FAP expression with persistence of FAP expression observed despite tumor response
Further data updates expected in Q3 2026
You might also wanna read
Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients
An experimental drug called daraxonrasib has become the first treatment to substantially extend the lives of pancreatic cancer patients in a
nytimes.com·17d ago
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug blocks
bit.ly·1mo ago
Daraxonrasib nearly doubles survival in advanced pancreatic cancer by targeting previously 'undruggable' mechanism
A new drug called daraxonrasib has shown promise in nearly doubling survival rates for patients with advanced pancreatic cancer. Pancreatic
theconversation.com·27d ago
New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
A new daily pill called daraxonrasib, which targets a gene behind pancreatic cancer, nearly doubled overall survival time for patients with
to.pbs.org·29d ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.